Craft
Nohla Therapeutics

Nohla Therapeutics

Total Funding

$64.5 M

Nohla Therapeutics Summary

Company summary

Overview
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
Type
Private
Status
Closed
Founded
2015
HQ
Seattle, WA, US | view all locations
Website
https://nohlatherapeutics.com/
Cybersecurity rating
Sectors

Key people

  • Kathleen Fanning

    Kathleen Fanning, President and Chief Executive Officer

    • Colleen Delaney

      Colleen Delaney, Founder and Chief Scientific Officer, Executive Vice President of Research and Development

      • Sarah Noonberg, Chief Medical Officer

        • Gary Christianson, Chief Operating Officer

          LocationsView all

          3 locations detected

          • Seattle, WA HQ

            United States

            1600 Fairview Ave E

          • Melbourne, Victoria

            Australia

            16 Queen St

          • South Melbourne, Victoria

            Australia

            16 10 Queen St

          Footer menu